Skip to main content
. Author manuscript; available in PMC: 2010 May 18.
Published in final edited form as: Vaccine. 2009 Apr 5;27(23):3026–3034. doi: 10.1016/j.vaccine.2009.03.036

Figure 3. Mice immunized with BCG and lactoferrin demonstrate long lasting diminished inflammation and destructive pulmonary histopathology upon challenge with virulent MTB.

Figure 3

C57BL/6 mice demonstrated reduced histological manifestation of disease in the BCG and recombinant lactoferrin immunized groups at day 150 post aerosol challenge. The panels depict histopathology from non-immunized controls and those immunized with BCG vaccine alone, or immunized with the human milk-derived lactoferrin, or recombinant human lactoferrins (non-sialylated or sialylated). The human recombinant lactoferrin adjuvant immunized mice revealed striking reduction in granulomas with evidence of lymphocytic clusters and contained focal pockets of inflamed monocytes. Tissue was sectioned and stained with H&E (20×, left; 100×, right). Representative pathology from one mouse per immunization group shown, examining 5–10 mice per group.